The development and clinical use of PD-1 or PD-L1 inhibitors, such as nivolumab and pembrolizumab, permit activated T cells to overcome these immune regulatory mechanisms and mount anti-tumor responses [29]. This evidence concerns the gene PDCD1 and neoplasm.